Full-Time

Environmental Monitoring Supervisor

Updated on 8/20/2026

Indivior

Indivior

501-1,000 employees

Pharma: treats addiction and mental illness

Compensation Overview

$88k - $95.7k/yr

+ Bonus + Profit-sharing contribution + Equity + Employee stock purchase plan

Raleigh, NC, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Microbiology

Get referred to Indivior

See people who can refer or advise you

Requirements
  • A bachelor's degree in microbiology, biological sciences, or a related field is required.
  • Requires three to five years of progressive laboratory or environmental monitoring responsibility supporting pharmaceutical manufacturing, or equivalent related industrial or clinical experience.
  • Must be knowledgeable of quality control testing methods, validation techniques, and microbiology concepts.
  • Must be able to understand and scientifically interpret data using analytical skills and practical experience in pharmaceutical applications.
  • Must have demonstrated leadership and supervisory skills.
  • Excellent verbal and written communication skills are essential.
  • Must be able to meet the physical requirements, including continuous computer use and typing, routine walking between offices, laboratories, and operational areas, occasional lifting and carrying of less than 10 pounds, and wearing appropriate protective apparel in manufacturing, processing, or drug-product holding areas.
Responsibilities
  • Supervise the daily activities of environmental monitoring technicians and ensure deadlines, quality concerns, and questions are addressed.
  • Maintain the system for monitoring and trending environmental data and ensure data approval is completed.
  • Ensure proper and timely collection of environmental and site utility samples.
  • Participate as the environmental monitoring representative during internal and regulatory audits.
  • Create environmental monitoring summary reports to support site and product filings.
  • Instruct new-employee gowning classes.
  • Instruct the Aseptic Process Area gowning class and approve new employees to start Aseptic Process Area qualification.
  • Ensure employees entering the Aseptic Process Area are gown-qualified or requalified and participate in annual media fills.
  • Assess planned repair work in classified areas and complete Quality Control Approval of Change Work Orders for the work.
  • Ensure environmental monitoring data review and approval is completed and delivered to Microbiology Quality Assurance to support the weekly System Release process.
  • Hire and oversee training of department personnel, maintain personnel morale and development, and conduct performance evaluations.
  • Ensure execution of monitoring and testing programs assessing microbiology quality parameters of in-process and environmental systems and production-process effectiveness.
  • Establish goals for timely product release and project performance, monitor group performance against goals, and implement corrective action.
  • Ensure products or environmental systems not meeting specifications or limits are promptly investigated.
  • Identify possible sources and required corrective actions and evaluate their impact on the lot.
  • Identify significant adverse quality trends by preparing and analyzing summary reports.
  • Address quality-control test results and microbial profiles of environmental systems.
  • Generate and update Standard Operating Procedures.
  • Maintain current knowledge of current good manufacturing practices and regulatory issues and guidelines.
  • Ensure the department has functional, calibrated equipment and necessary supplies.
  • Supervise investigations of out-of-specification results and environmental excursions.
  • Ensure adequate evaluation of new product processes.
  • Represent the department in cross-functional teams and meetings.
  • Perform other duties and projects assigned by management.
Desired Qualifications
  • Experience in aseptic processing is preferred.
  • Supervisory experience is preferred.

Indivior focuses on developing medicines for substance use disorders and serious mental illnesses. Its products are prescription pharmaceutical treatments, brought to market after research and development, and sold through healthcare professionals to patients worldwide. The company’s approach centers on patient safety, with ongoing monitoring and reporting of adverse events to ensure high-quality therapies. Compared with competitors, Indivior emphasizes targeted medicines for addiction and mental health, combining scientific R&D with a global commercialization presence to address critical healthcare needs. Its goal is to create sustainable value by improving patient outcomes and addressing unmet medical needs in global health.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Bon Air, Virginia

Founded

2014

Get referred to Indivior

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • First-quarter 2026 revenue rose 19% to $317 million, with EBITDA jumping 112%.
  • SUBLOCADE delivered record 31,800 new starts in Q1 2026 and 32% revenue growth.
  • Indivior's August 2026 merger creates $125 million annual synergies and $1 billion dividend cash.

What critics are saying

  • The merger still needs shareholder and antitrust approvals, and Q4 2026 closing remains uncertain.
  • SUBLOCADE drives most value; any safety, reimbursement, or prescriber disruption hits revenue immediately.
  • The company abandoned INDV-6001 and INDV-2000 in 2026, exposing thin pipeline replacement risk.

What makes Indivior unique

  • SUBLOCADE dominates monthly injectable buprenorphine, crossing 500,000 U.S. prescriptions by March 2026.
  • Indivior built restricted-distribution addiction infrastructure, including REMS-certified dispensing and correctional-facility commercialization.
  • The August 3, 2026 Supernus merger adds CNS diversification across eleven marketed medicines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Holidays

Paid Sick Leave

Flexible Work Hours

Remote Work Options

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Adoption Assistance

Tuition Reimbursement

Employee Stock Purchase Plan

401(k) Company Match

Profit Sharing

Legal Services

Pet Insurance

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
BizWire Express
Aug 3rd, 2026
BizWire Express > - Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

BizWire Express - Bringing you the latest news as it happens from all over the world.

Finimize
Aug 3rd, 2026
Supernus and Indivior agree to an all-stock merger.

Supernus and Indivior agree to an all-stock merger. Indivior plans a $1 billion special dividend before closing, with the combined company set to trade as SUPN and target $125 million in annual cost savings. about 1 hour ago - 1 min What's going on here? Supernus Pharmaceuticals and Indivior said Monday they'll merge in a tax-free, all-stock deal, but Indivior plans to send shareholders a $1 billion special dividend before the tie-up closes in Q4. What does this mean? Both boards have unanimously approved the merger, which values the combined company around scale and efficiency rather than a simple cash takeover. Under the terms, Supernus shareholders will receive 1.5401 Indivior shares per Supernus share, leaving Indivior owners with about 56.5% of the new business. Indivior will also pay a one-time $1 billion dividend before closing, partly funded by a new $650 million term loan - a way to return cash now w... Keep reading for free. This content is free, but you must be logged in to continue reading. Already have an account?

Yahoo Finance
Aug 3rd, 2026
Supernus reports 32% revenue jump to $219M, announces merger with Indivior

Supernus Pharmaceuticals reported total revenues of $219.1 million for Q2 2026, up 32% year-over-year. Combined revenues from the company's four growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—reached $175.7 million, marking a 52% increase compared to Q2 2025. ONAPGO generated $13.5 million in net product sales during the quarter. Since launching in April 2025, the product has attracted approximately 2,600 enrollment forms from around 720 prescribers through end-July 2026. ZURZUVAE collaboration revenue totalled $35.4 million in Q2 2026, representing 50% of Biogen's net revenues for the product. US sales of ZURZUVAE increased approximately 53% year-over-year. Supernus raised its full-year 2026 financial guidance and announced a merger agreement with Indivior Pharmaceuticals to create a diversified CNS biopharmaceutical company.

Minichart
Aug 3rd, 2026
Supernus Pharmaceuticals Reports 32% Revenue Surge, Raises Guidance, and Announces Merger with Indivior Pharmaceuticals in Q2 2026

Supernus Pharmaceuticals Q2 2026 Earnings & Major Merger Announcement

Yahoo Finance
Jun 14th, 2026
Indivior CSO sells 18,586 shares worth $707K amid 177% one-year stock surge

Indivior Pharmaceuticals' Chief Scientific Officer Christian Heidbreder sold 18,586 shares in an open-market transaction on 11 June 2026 at $38.06 per share, according to an SEC Form 4 filing. The sale represented 7.54% of his direct holdings. Following the transaction, Heidbreder retains 227,923 shares valued at approximately $8.69 million, maintaining a 0.18% ownership stake in the company. The sale occurred after Indivior's shares delivered a 177% one-year total return, rising from a 52-week low of $13.45 to reach $41 in May. Indivior develops buprenorphine-based medications for opioid dependence treatment, including Suboxone Film and Subutex Tablet. The company reported $1.29 billion in trailing twelve-month revenue and $252 million in net income.